Royce & Associates LP Increases Stock Position in Cara Therapeutics, Inc. (NASDAQ:CARA)

Royce & Associates LP increased its position in Cara Therapeutics, Inc. (NASDAQ:CARAGet Rating) by 744.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,592 shares of the biopharmaceutical company’s stock after buying an additional 98,370 shares during the period. Royce & Associates LP owned about 0.21% of Cara Therapeutics worth $1,356,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Baldwin Brothers LLC MA raised its position in shares of Cara Therapeutics by 41.0% in the first quarter. Baldwin Brothers LLC MA now owns 18,327 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 5,327 shares during the last quarter. Woodstock Corp raised its position in shares of Cara Therapeutics by 17.8% in the first quarter. Woodstock Corp now owns 35,522 shares of the biopharmaceutical company’s stock valued at $432,000 after buying an additional 5,373 shares during the last quarter. Pinnacle Associates Ltd. raised its position in shares of Cara Therapeutics by 12.9% in the fourth quarter. Pinnacle Associates Ltd. now owns 382,478 shares of the biopharmaceutical company’s stock valued at $4,659,000 after buying an additional 43,556 shares during the last quarter. Davy Global Fund Management Ltd raised its position in shares of Cara Therapeutics by 11.7% in the fourth quarter. Davy Global Fund Management Ltd now owns 174,948 shares of the biopharmaceutical company’s stock valued at $2,131,000 after buying an additional 18,323 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Cara Therapeutics in the fourth quarter valued at approximately $4,364,000. Institutional investors and hedge funds own 56.56% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 13th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $26.80.

Cara Therapeutics Stock Up 8.0 %

Shares of CARA stock opened at $11.27 on Friday. Cara Therapeutics, Inc. has a one year low of $7.40 and a one year high of $18.93. The company has a 50 day moving average price of $8.99 and a 200 day moving average price of $10.25.

Cara Therapeutics (NASDAQ:CARAGet Rating) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.04. The business had revenue of $4.79 million during the quarter, compared to analyst estimates of $15.82 million. During the same period in the previous year, the company earned ($0.47) EPS. Equities analysts predict that Cara Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Insider Transactions at Cara Therapeutics

In other news, Director Jeffrey L. Ives sold 3,600 shares of the stock in a transaction on Friday, July 15th. The shares were sold at an average price of $9.05, for a total value of $32,580.00. Following the completion of the sale, the director now owns 15,476 shares of the company’s stock, valued at $140,057.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.20% of the company’s stock.

Cara Therapeutics Profile

(Get Rating)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Read More

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.